Treatment of progressive supranuclear palsy
On 16 July 2016 NeuroTau Inc. obtained US FDA orphan drug designation for tolfenamic acid in the treatment of Progressive Supranuclear Palsy (PSP)
Public summary of opinion on orphan designation – Tolfenamic acid for the treatment of progressive supranuclear palsy
On 17 February 2016, NeuroTau partner was granted orphan designation (EU/3/16/1613) by the European Commission for tolfenamic acid for the treatment of progressive supranuclear palsy.
Treatment of Frontotemporal Dementia
On 16 July 2016 NeuroTau Inc. obtained US FDA orphan drug designation for tolfenamic acid in the treatment of Frontotemporal Dementia (FTD)
Public summary of opinion on orphan designation – Tolfenamic acid for the treatment of behavioural variant frontotemporal dementia
On 17 February 2016, NeuroTau Inc partner was granted orphan designation (EU/3/16/1614) by the European Commission for tolfenamic acid for the treatment of behavioural variant frontotemporal dementia.
Evaluation of Tolfenamic Acid in Individuals With PSP at 12-Weeks
NeuroTau Inc announces listing of its clinical trial “Evaluation of Tolfenamic Acid in Individuals with Progressive Supranuclear Palsy (PSP)” on ClinicalTrials.gov and intention to begin study in Q1/2021
